The Ames Test in Twenty-first Century
DOI:
https://doi.org/10.37591/rrjot.v2i1.1289Abstract
Since the 19th century, industrial development has increased exposure to mutagens and possible carcinogens. In order to avoid these health risks, several techniques have been developed to recognize genotoxins. In the 1970s, Dr. Bruce Ames and colleagues, studying the histidine operon of Salmonella typhimurium, observed that histidine (−) auxotroph mutants were reverted to histidine (+) upon exposure to a mutagen. The researchers further observed that known carcinogens were mutagenic to S. typhimurium strains. The Ames test has since been employed as a first step in evaluating genotoxic risk. The Ames method has been accepted by several international organizations including the IARC (International Agency of Cancer Research), EPA (Environmental Protection Agency), FDA (Food and Drug Administration), IVGT (In Vitro Genetic Toxicity Testing Project), REAC (European Union Legislation, Registration, Evaluation, Authorization and Restriction of Chemicals), and the Japanese Ministry of Health and Welfare (MHW). Occasionally, research of new products is suspended upon a positive Ames test result. The Ames test has also been improved to evaluate DNA repair mechanisms using S. typhimurium uvrB + /uvrB− strains. Additionally, researchers have genetically modified these strains to investigate metabolic mechanisms that convert pre-mutagens to active mutagens. The Ames test has also been useful for studying alternatives to reduce genotoxic risk. It is widely employed for antimutagenic evaluation and elucidation of their mechanisms of action. Knowledge on antimutagens is important to reduce mutagenic risk of genotoxic compounds which cannot be avoided, such as therapeutic drugs. A major pitfall of the Ames test is the correlation of data obtained from prokaryotic cells and eukaryotic cells. The aim of this review is to analyze the advantages of the Ames test as a method for studying several aspects of genetic toxicology.
Keywords: Ames test, risk evaluation, mutagenesis, antimutagenesis
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |